ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1309

Interstitial Pneumonia with Autoimmune Features: Is It Frequent?

John Fredy Jaramillo Gallego1, Marina Scolnik2, Joaquin Maritano Furcada3, Maria Laura Acosta Felquer4, Nicolas Martin Marin Zucaro1, Luciano Fernando Lo Giudice1 and Enrique R Soriano2, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, 2Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, 3Pneumology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, 4Rheumatology Unit, Internal Medicine Service,, Hospital Italiano de Buenos Aires, Capital Federal, Argentina

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: interstitial lung disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: A particular subset of interstitial pneumonia, associated to one or more clinical and serological features, suggesting a possible underlying autoimmune disorder, has been described and recently named Interstitial Pneumonia with Autoimmune Features (IPAF). Its prevalence and prognosis remains controversial and seems to include a very heterogeneous population. Our objective was to evaluate patients with interstitial lung involvement seen at a university hospital in Latin America in order to determine IPAF frequency and characteristics.

Methods: All electronic medical records of patients seen by pneumonologists during a 1 year at our hospital because of an interstitial lung disease (ILD) were reviewed by a rheumatologist and a pneumonologist in conjunction. Patients were classified in 3 groups: Idiopathic Pulmonary Fibrosis (IPF), IPAF and Interstitial Pneumonia associated with a connective tissue disease (IP-CTD). Demographic and clinical data, images features, lung function tests, and survival were recorded. Patients’ characteristics were compared between groups and a multivariate logistic regression analysis was performed in order to identify associations with an autoimmune ILD.

Results: 80 patients were seen in 1 year with ILD: 31 with IFP (38.8%), 3 with IPAF (3.8%) and 46 (57.5%) with IP-CTD. Patients’ characteristics are shown in table 1. Rheumatologic diseases with IP-CTD were Lupus in 2 patients, Mixed Connective Tissue Disease in 6, Limited Systemic Sclerosis in 2, Diffuse Systemic Sclerosis in 19 and 1 Inflammatory Myopathy. During a median follow up of 4.8 years (IQR 3.8-6.9) after ILD diagnosis, 5 patients died (6.3%): 3 with IFP and 2 with IP-CTD. Gender, Age and Physiology score (GAP) was associated with mortality as it has been previously described (OR 1.76, 1.02-3.07). In patients with IFP, CT pattern was UIP in 41.9% (CI 25.7-60.1%) and NSIP in 35.5 % (CI 20.5-54.0%). On the other hand, patients with IP-CTD, NSIP was the most frequent pattern in 60.0% (CI 44.8-73.5%), and 24.4% (13.9-39.4%) had an UIP pattern. Although NSIP was more frequent in autoimmune related ILD, it was not independently associated to it. In the multivariable logistic regression analysis female sex (OR 10.5, CI 2.75-40.15) and a younger age (OR 0.94, CI 0.89-0.98) were associated with an autoimmune ILD diagnosis.

Conclusion: when evaluated together by a rheumatologist and a pneumonologist, IPAF diagnosis was very rare (3.8%). An autoimmune ILD disease must be suspected in females and younger patients.

Idiopathic Pulmonary Fibrosis (n=31)

Interstitial pneumonia with autoimmune features (n=3)

Interstitial Pneumonia associated with a connective tissue disease (n=46)

p

Mean Age at interstitial lung disease diagnosis (ILD), (SD)

68.2 (10.9)

69.2 (3.6)

55.3 (16.6)

0.01

Female, n (%)

14 (45.2)

2 (66.7)

43 (93.5)

<0.01

Median Follow up after interstitial lung disease diagnosis, years, (IQR)

4.5 (3.7-5.7)

6.6 (4.3-7.5)

5.1 (3.8-6.9)

0.50

Death during follow-up, n (%, CI)

3 (9.7, 3.0-26.8)

0

2 (4.3, 1.0-16.3)

0.58

Ever smoker, n (%, CI)

13 (41.9, 25.7-60.1)

3 (100)

14 (30.4, 18.7-45.5)

0.04

Corticosteroid treatment because of ILD, n (%, CI)

23 (74.2, 55.6-86.8)

2 (66.7, 9.2-97.5)

31 (67.4, 52.3-79.6

0.81

Immunosuppressant treatment because of ILD, n (%, CI)

10 (32.3, 17.9-50.9)

1 (33.3, 2.5-90.8)

23 (50.0, 35.6-64.4)

0.30

First Vital Force Capacity (VFC), %, median (IQR)

73 (63-80)

97 (85-120)

81 (74-97)

0.01

Last Vital Force Capacity (VFC), %, median (IQR)

70 (60-81)

83 (58-94)

77(57-90)

0.45

Decline in VFC >10% during follow-up, n (%, CI)

8 (28.6, 14.6-48.3)

1 (33.3, 24.4-90.9)

10 (25.6, 14.1-41.9)

0.94

First Diffusing capacity of the lung for carbon monoxide (DLCO),

%, median (IQR)

62 (51-70)

64 (48-74)

72 (61-81)

0.01

Last Diffusing capacity of the lung for carbon monoxide (DLCO),

%, median (IQR)

52 (44-64)

48 (45-52)

64 (53-70)

0.05

Non-specific interstitial pneumonia at chest CT, n (%, CI)

11 (35.5, 20.5-54.0)

3 (100)

27 (60.0, 44.8-73.5)

0.03

GAP Index for Idiopathic Pulmonary Fibrosis (IPF), median (IQR)

4 (3-5)

3.5 (3-4)

2 (1-3)

<0.001


Disclosure: J. F. Jaramillo Gallego, None; M. Scolnik, None; J. Maritano Furcada, None; M. L. Acosta Felquer, None; N. M. Marin Zucaro, None; L. F. Lo Giudice, None; E. R. Soriano, AbbVie, Bristol-Myers Squibb, GSK, Janssen, Novartis, Pfizer Inc, Roche, UCB, 2,AbbVie, Bristol-Myers Squibb, Eli Lilly, GSK, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, 5,AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sandoz, UCB, 8.

To cite this abstract in AMA style:

Jaramillo Gallego JF, Scolnik M, Maritano Furcada J, Acosta Felquer ML, Marin Zucaro NM, Lo Giudice LF, Soriano ER. Interstitial Pneumonia with Autoimmune Features: Is It Frequent? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/interstitial-pneumonia-with-autoimmune-features-is-it-frequent/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interstitial-pneumonia-with-autoimmune-features-is-it-frequent/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology